An interventional study of Treatment interruption in HIV, sponsored by Fundacion Clinic per a la Recerca Biomédica. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Fundacion Clinic per a la Recerca Biomédica · Not applicable, Interventional, and Treatment
A pilot single exploratory clinical trial of ATI in a selected sample of PWH sharing specific genetic, phenotypic and clinical characteristics.
Fundacion Clinic per a la Recerca Biomédica is the lead sponsor of 64 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Having a favourable genotype AND a favourable NK phenotype defined by
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Antiretroviral treatment interruption in people with HIV with a highly favorable profile
Other: Treatment interruption
Antiretroviral treatment interruption in people with HIV with a highly favorable profile
Proportion of individuals with VL<50 copies.
Time frame: At 24 weeks of ATI
To determine the proportion of patients with partial viral control up to 24 weeks (< 200, < 400 and <1000 copies/ml) of ATI.
Proportion of participants with VL \< 200, \<400 copies/ml and VL \<1000 copies/ml
Time frame: At 24 weeks post-ATI
To determine time to rebound after ATI.
Time (in weeks) to viral rebound (VL≥ 50).
Time frame: From the start of Analytical Treatment Interruption (ATI) up to 24 weeks.
Proportion of participants with clinical symptoms during Analytical Treatment Interruption (ATI).
Percentage of participants experiencing any clinical symptom or retroviral syndrome during ATI.
Time frame: From the start of Analytical Treatment Interruption (ATI) up to 24 weeks.
To study the HIV reservoir.
Evolution of the viral reservoir as measured by IPDA and intracellular viral RNA.
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
To study viral inhibition in CD4 counts.
Viral inhibition "in vitro" (VIA assays) culturing CD4 lymphocytes in the presence of CD8 and/or NK lymphocytes.
Time frame: At weeks 0, 4, 12, 24., 36 and 48.
Percentage of senescent CD8+ T lymphocytes
Change from baseline in the percentage of senescent CD8+ T cells (defined as CD8+CD57+) out of the total CD8+ T lymphocyte population, assessed by flow cytometry.
Time frame: At weeks 0, 4, 12,24, 36 and 48.
Percentage of memory-like Natural Killer (NK) cells.
Change from baseline in the percentage of memory-like NK cells (defined by the expression of CD57+CD56+dim, NKG2C+, and KIR3DL1+) out of the total NK cell population, assessed by flow cytometry.
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
Percentage of gamma-delta (γδ) CD8+ T cells.
Change from baseline in the percentage of CD8+ T cells expressing the γδ T-cell receptor (TCR) out of the total CD8+ T lymphocyte population, assessed by flow cytometry.
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
Transcriptomic profiles in different lymphocyte subsets.
Analysis of transcriptomic characteristics in different lymphocyte subsets by Next-Generation Sequencing (NGS).
Time frame: At weeks 0, 4, 12, 24, 36 and 48
Serum levels of immunosenescence markers.
Change from baseline of serum immunosenescence-related markers, including Interleukin-8 (IL-8), Monocyte Chemoattractant Protein-1 (MCP-1), C-C Motif Chemokine Ligand 5 (CCL5), and C-X-C Motif Chemokine Ligand 1 (CXCL1), assessed by laboratory analysis. Units: Picograms per milliliter (pg/mL).
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
Serum levels of IL-6 and TNF-alpha.
Change from baseline of serum inflammatory and immune activation markers, including Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha), assessed by laboratory analysis. Units: Picograms per milliliter (pg/mL)
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
Serum levels of soluble CD14 and soluble CD163.
Change from baseline of serum inflammatory and immune activation markers, including soluble CD14 (sCD14) and soluble CD163 (sCD163), assessed by laboratory analysis. Units: Nanograms per milliliter (ng/mL).
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
Serum levels of C-Reactive Protein (CRP).
Change from baseline of C-Reactive Protein (CRP) in serum samples, assessed by laboratory analysis. Units: Milligrams per deciliter (mg/dL).
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
Change from baseline of autologous neutralizing antibodies.
Measurement of autologous neutralizing antibody levels to evaluate changes from baseline.
Time frame: At weeks 4, 8, 12, 24, 36 and 48
Predictive model for post-treatment viral control.
Probability score generated by the statistical integration of clinical, genetic, immunologic, and virologic parameters to predict post-treatment control. The final mathematical model will yield an estimated probability of maintaining viral control, where 100% indicates the maximum probability of control. Units: Percentage (%).
Time frame: From the start of Analytical Treatment Interruption (ATI) up to 24 weeks.
Characterization of the cytotoxic activity of CD4, CD8 and cellular proliferation after stimulation with HIV peptides as compared to basal levels.
Time frame: At weeks 4, 12, 24, 36 and 48
Cytotoxic activity of NK cells as assessed by anti-HIV peptide responses, granzyme production and killing of K562 and Raji cells.
Time frame: At weeks 0, 4, 12, 24, 36 and 48.
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion Clinic per a la Recerca Biomédica